EGM
XLO icon

Engineers Gate Manager’s Xilio Therapeutics XLO Stock Holding History

Engineers Gate Manager’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,339
Closed -$25.8K – 2625
2024
Q3 		$25.8K Buy
+2,339
New +$28.7K ﹤0.01% 2014

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Engineers Gate Manager's XLO Position: Q4 2024 in Review

Engineers Gate Manager sold out of Xilio Therapeutics (XLO) in Q4 2024, closing a stake of 2,339 shares — an estimated $25.8K sold.

Engineers Gate Manager first reported a position in XLO in Q3 2024 and held it in 1 quarter. The position peaked at $25.8K in Q3 2024. 35 funds tracked by Wall St. Rank hold XLO as of Q4 2024.

  • Engineers Gate Manager reported no remaining Xilio Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 2,339 Xilio Therapeutics shares in Q4 2024, an estimated $25.8K.
  • Engineers Gate Manager first reported a position in Xilio Therapeutics in Q3 2024 and held it in 1 quarter.
  • Engineers Gate Manager's Xilio Therapeutics position peaked at $25.8K in Q3 2024.
  • 35 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2024.

Based on Engineers Gate Manager's 13F filing for Q4 2024, filed 14 Feb 2025.